SecBot SecBot
PRESS-RELEASE ·Filed May 12, 2026

ZNTL

ZENTALIS PHARMACEUTICALS
BULLISH
Impact 7/10
Horizonmonths Processed6mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▲ Bullish

The dose selection and ASPENOVA initiation de-risk the regulatory pathway for azenosertib. The DENALI topline readout by year-end 2026 is the next major catalyst, positive data could drive significant upside given the 50% PROC patient population with no approved biomarker-specific therapy. Monitor for FDA feedback on accelerated approval and any partnership or financing announcements given the cash runway into late 2027.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$4.28
T+0 close · May 12, 2026 · via day close
Latest settled
−1.40%
T+60 · $4.22
Vs SPY
−5.84%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 13 $4.28entry
  2. T+1 · 6mo ago 0.00%α +0.00% · $4.28
  3. T+5 · 6mo ago −17.29%α −16.13% · $3.54
  4. T+20 · 5mo ago −17.76%α −17.14% · $3.52
  5. T+60 · 3mo ago −1.40%α −5.84% · $4.22
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Zentalis reported Q1 2026 EPS of -$0.50, beating consensus of -$0.52 by 4.5%, with no revenue. The key catalyst is the selection of the 400mg QD 5:2 dose for azenosertib monotherapy in Cyclin E1-positive PROC, advancing the DENALI Phase 2 trial toward a topline readout by year-end 2026, which could support an accelerated approval pathway. Cash of $211.8M provides runway into late 2027, funding key milestones including the ASPENOVA Phase 3 trial initiation.

Key Financial Metrics

EPS
−$0.50
est −$0.52 · +3.9%
Rating
beat

Key Facts

  • Q1 2026 EPS -$0.50 vs consensus -$0.52 (4.5% beat)
  • Selected 400mg QD 5:2 as pivotal dose for azenosertib monotherapy in Cyclin E1-positive PROC
  • DENALI Part 2 topline readout expected by year-end 2026, potentially supporting accelerated approval
  • ASPENOVA Phase 3 confirmatory trial initiated with first patient dosed
  • Cash, cash equivalents and marketable securities of $211.8M as of March 31, 2026, providing runway into late 2027
  • R&D expenses $28.7M in Q1 2026 vs $27.2M in Q1 2025; total operating expenses $37.9M vs $45.6M
  • Net loss $35.4M in Q1 2026 vs $48.3M in Q1 2025

Financial Impact

EPS beat of $0.02 per share; cash burn of ~$34M in Q1 2026; no revenue reported

epscashoperating expenses

Risk Factors

  • DENALI Part 2 topline data may not meet efficacy endpoints required for accelerated approval
  • Competition from other WEE1 inhibitors and emerging therapies in PROC
  • Cash runway only into late 2027; may require additional financing before reaching profitability
  • Regulatory delays or changes in FDA accelerated approval requirements

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
60% bullish (15 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3293397

Track record

18 reports on ZNTL

Performance horizon

5 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +51.42% at T+60 after the Aug 14, 2026 report. 6 of 9 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 4/10 Entry $1.62 Now $1.60 −1.23% settles Feb 12
  2. Nov 9, 20267d ago 8-K Bearish 5/10 Entry $1.80 Now $1.60 +11.11% settles Feb 8
  3. Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $2.06 Now $1.60 −22.33% settles Jan 26
  4. Oct 18, 202629d ago Press Release Bullish 7/10 Entry $2.30 Now $1.60 −30.43% settles Jan 14
  5. Oct 1, 20266w ago Press Release Neutral 2/10 Entry $2.52 Now $1.60 −36.51% settles Dec 29
  6. Aug 14, 202613w ago 8-K Bearish 6/10 Entry $3.71 to $1.80 Now $1.60 +56.82% ▲ +51.42% +48.47% vs SPY
  7. Aug 13, 202613w ago Press Release Bearish 6/10 Entry $3.56 to $1.74 Now $1.60 +55.06% ▲ +51.12% +48.08% vs SPY
  8. Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $3.75 to $4.03 Now $1.60 −57.33% ▲ +7.47% +4.20% vs SPY
  9. Jun 1, 202624w ago Press Release Neutral 2/10 Entry $3.95 to $3.89 Now $1.60 −59.49% ▼ −1.52% −2.64% vs SPY
  10. May 21, 202625w ago Press Release Bullish 6/10 Entry $4.06 to $3.68 Now $1.60 −60.59% ▼ −9.36% −12.55% vs SPY
Showing 10 of 18

US Market Status

Market Closed · Opens in 9h 1m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 12, 2026